A major challenge in human genetics is the prioritization of causal genes in common complex diseases. A genome-wide CRISPR screen for intracellular insulin content in a human β-cell line has now identified a new candidate gene for type 2 diabetes, demonstrating the utility of this screening approach in β-cells.
This is a preview of subscription content, log in via an institution to check access.
References
Grotz, A. et al. Curr. Diab. Rep. 17, 76 (2017).
Barroso, I. & McCarthy, M. I. Cell 177, 146–161 (2019).
Rottner, A. K. et al. Nat. Genet. https://doi.org/10.1038/s41588-022-01261-2 (2022).
Ravassard, P. et al. J. Clin. Invest. 121, 3589–3597 (2011).
Udler, M. S. et al. PLoS Med. 15, e1002654 (2018).
Fang, Z. et al. Cell Rep. 26, 3132–3144 (2019).
Cai, E. P. et al. Nat. Metab. 2, 934–945 (2020).
Bevacqua, R. et al. Nat. Commun. 12, 2397 (2021).
Krentz, N. A. J. & Gloyn, A. L. Nat. Rev. Endocrinol. 16, 202–212 (2020).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wagner, B.K. Identifying type 2 diabetes risk genes by β-cell CRISPR screening. Nat Genet 55, 4–5 (2023). https://doi.org/10.1038/s41588-022-01269-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-022-01269-8
- Springer Nature America, Inc.